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chronic cigarette smoke exposure; emphysema; liver growth factor; mice model; therapy CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) is a major cause of illness and death throughout the world, with the main risk factor as cigarette smoke, and increasing evidence suggests that COPD is a disease characterized by both local and systemic inflammation. Systemic inflammation in COPD is characterized by cytokines implicated in inflammatory cell recruitment and airway remodeling. Reduced lung function is associated with increased levels of various systemic inflammatory markers (16) . Emphysema, a component of COPD, is characterized by an inflammatory cell infiltrate and by the presence of proteinases in excess within the alveolar space, which leads to destruction of alveolar walls and permanent enlargement of the peripheral airspaces of the lung, and no treatment is currently available to reverse the lung destruction and induce proper healing. The target of newer treatments being developed is primarily directed toward stopping the worsening of the disease, either by inhibiting inflammation and the overproduction of mucus, or by employing antioxidant and antifibrotic agents (3) .
Liver growth factor (LGF) was identified as an albuminbilirubin complex with mitogenic properties in rat liver (12) . It has antifibrotic, antioxidant, and antihypertensive properties, and its regenerative effects have been described in several rodent models, including hepatic damage (13, 14) , cardiovascular diseases such as hypertension and atherosclerosis lesions (7, 8, 42 ), Parkinson's disease (17, 38, 39) , and testicular degeneration (32) . On the other hand, data published in lung fibrosis by our group show the antifibrotic effects of LGF in rats induced with ClCd 2 (30) . Considering the regenerative activity in different systems, LGF could be suggested as a promising choice for the stimulation of processes involved in tissue repair in previously damaged lungs in a known model of COPD in mice. Therefore, our goal is to test the effects of LGF administration in a mouse model of emphysema induced by chronic cigarette smoke exposure (CSE).
In several investigations, it has been shown that the development of emphysema in mice chronically exposed to cigarette smoke is highly dependent on the mouse strain and dose (20, 47) . In this regard, the AKR/J strain was shown to be extremely susceptible to the development of emphysema, as measured by increases in the airspace enlargement and the elastic properties of the lung, after chronic exposure to cigarette smoke (20) . Likewise, the cellular and molecular inflammatory response was also shown to be more prominent in the lungs of the AKR/J mice chronically exposed to cigarette smoke than in the other mouse strains investigated in the study in question (20) .
Fluorescence molecular imaging (FMI) is the method of choice for functional, real-time, in vivo monitoring of matrix metalloproteinase (MMP) activity because it provides an "easy" approach for measuring enzymatic activities (21, 29, 45) . Here we use an injectable pan-MMP-targeted optical sensor that specifically and semiquantitatively resolves MMP-2, -3, -9, and -13 activities that initiate and propagate inflammatory responses (11, 19, 27, 33) in the lungs of mice with experimental chronic CSE-induced emphysema. Several studies have suggested that MMPs are the critical mediators of CSE-induced emphysema (11, 24, 41) .
The purpose of this study was to demonstrate the therapeutic effect of LGF treatment improving the inflammatory status, visualized and quantified by in vivo FMI in the lung of a chronic inflammation after CSE-induced emphysema in AKR/J mouse model, including improvement of lung function and morphometry parameters.
MATERIALS AND METHODS
Animals. Thirty adult, 8-wk-old male AKR/J mice, 25-27 g body wt (The Jackson Laboratory, Bar Harbor, ME), were divided in three groups (n ϭ 10/group): control (CTL), CSE, and CSE with LGF treatment (CSE ϩ LGF). Animals were housed in the Inhalation Core Facility at IIS-Fundación Jiménez Díaz for 1 wk of acclimatization before the experimental procedures. After daily exposure, mice were returned to their cages, where a diet of alfalfa-free rodent food (Harlan Teklad) and water were provided ad libitum. Protocols were approved by the local Ethical Animal Research Committee at IIS-Fundación Jiménez Díaz. In all cases, the legislation regarding animal treatment, protection, and handling was followed (RD 53/2013). All animals were weighed on a monthly basis during the 6-mo study period. AKR/J mice after chronic CSE for 6 mo exhibited a significantly lesser increase in their body weights compared with the corresponding control animals. Indeed, at 6 mo, mice exposed to tobacco smoke presented a minor increase in their body weight gain, (34% of baseline weight) compared with the CTL group (65% of baseline weight) (4) . No significant differences were appreciated in the body weight gain in the group of mice treated with LGF.
Chronic CSE-induced emphysema model. Chronic CSE was performed in 20 AKR/J mice (CSE group) with a daily exposition, 5 days a week, during a continuous period of 6 mo. The smoke from two consecutive (with 5-min breaks between them) standard research nonfiltered cigarettes was used (2R1, Cigarette Laboratory at the Tobacco and Health Research Institute, University of Kentucky, Lexington, KY), containing 11.7 mg total particulate matter per cubic meter of air, 9.7 mg tar, and 0.85 mg nicotine per cigarette. Mainstream CSE was generated by an exposure system and was drawn into the chambers via peristaltic pump, following previously published methodologies (4, 33, 35) . The whole body of the animals was exposed to research cigarettes according to the Federal Trade Commission protocol (1 puff/min of 2-s duration and 35-ml volume) with fresh air being pumped in for the remaining time. Chamber concentration of smoke constituents was ϳ158 mg/m 3 total suspended particulate. Nonsmoking control mice (CTL group, n ϭ 10) were exposed to filtered air in an identical chamber according to the sample protocol described for CSE.
Carboxyhemoglobin levels in blood samples after CSE confirm the correct exposition. Carboxyhemoglobin (COHb) formation is a wellrecognized effect of exposure to cigarette smoke. Increased levels of this form of hemoglobin indicate that the possibility of carbon monoxide poisoning should always be considered after exposure to cigarette smoke, and COHb levels should be routinely checked in such cases. On the other hand, relatively low levels of COHb and no clinical signs of carbon monoxide poisoning may suggest that, in our group, this kind of exposure did not play an important role. Therefore, immediately after removal of the animals from the smoke chamber, blood samples (ϳ50 l) were collected in a heparinized tube by puncturing the retroorbital sinus in randomized samples of four mice per group once a month. COHb levels were measured spectrophotometrically with an IL 682 CO-Oximeter (Instrumentation Laboratory) to confirm a nontoxic and effective exposure. Target values for COHb in blood samples of AKR/J mice after CSE were within nontoxic 7-9% range, confirming the correct exposure to tobacco smoke (4) . Importantly, on the basis of COHb blood measures, levels of smoke exposure were similar to those reported clinically (43) .
LGF treatment.
LGF was purified from serum of 5-wk bile ductligated rats following a previously reported procedure (15) . Purity, i.e., the absence of other growth factors and/or contaminants in the LGF preparation, was assessed according to standard criteria and activity checked before use. LGF preparations were lyophilized and stored at 4°C until used, at which time aliquots were dissolved in saline for intraperitoneal injection. The dose of LGF has been optimized in previous pilot experiments. Six months after CSE, when emphysema is once established, half of the smoker group animals were treated with four intraperitoneal injections (twice a week for 2 wk, n ϭ 10) of 150 l of a solution containing 1.7 g LGF per mouse (CSE ϩ LGF group) or saline solution (CSE group).
Lung function: lung compliance assessment. The animals were initially anesthetized with isoflurane and subsequently with a sodium pentobarbital, 50 mg/kg body wt ip (Abbott Laboratories). Mice were tracheotomized, and an endotracheal tube (22GA) was inserted and tied to their trachea. As soon as the mouse was connected to the breathing equipment, the animal was paralyzed with 0.2 mg of pancuronium bromide and artificially ventilated with a ventilator, designed and manufactured in the Universidad Complutense de Madrid and optimized for small rodents (26, 36) . Each animal was connected to the ventilator initially with a low tidal volume of 10 ml/kg. The normal breathing rate was set at a rate of 95 breaths/min, a moderate level of positive end-expiratory pressure (PEEP) of 4 cmH 2O was set to prevent alveolar collapse (atelectasis), and a pressure of 12 cmH2O on PEEP was applied to ensure an adequate level of ventilation. To prevent preexisting atelectasis and to facilitate comparisons between curves obtained from different subjects, the volume data were normalized by total lung capacity (TLC), defined as the static lung volume at an inflation pressure of 25 cmH2O (23, 25) . In this way, it was ensured that maximum lung capacity was reached without risking animal injury. For each animal, inspiration was controlled at a slow flow to 1 ml/s and free expiration. A new pressure-volume curve (P-V curve) cycle was started by pushing against air inside the lungs. This process was repeated for 30 s before the animal returned to normal mode of respiration. In this way, a total of seven to eight consecutive full P-V curves were acquired. Such a group of curves consists of one set of measurements. The changes in quasistatic lung compliance (CL, ml/cmH2O) after pressure-controlled ventilation were studied for each of the groups. Compliance was considered as the inflection point (maximum slope ⌬V/⌬P) in the expiratory limb of the curve, which brought closure pressure, at maximal alveolar derecruitment. The data were analyzed by fitting a sigmoidal function (22, 44) to the deflation limb of each P-V curve.
Morphometric analysis in lung tissue sections: mean linear intercept quantification. After the 6-mo study period, the cardiopulmonary block was excised and fixed by filling it with 10% formaldehyde at a constant airway pressure of 25 cmH2O (TLC) for 24 h. Fixed lungs were immersed in alcohol-xylol baths of different concentrations; thereafter paraffin-embedded lung 5-m-thick sections were cut using a microtome HM325 (Microm), stained with hematoxylin-eosin (Sigma-Aldrich Química) according to standard protocols, and were observed with an Olympus BX40 microscope. Images were visualized by an adapted video camera (Leica DFC290, Leica Microsystems) with a resolution of 782 ϫ 582 pixels (1 pixel ϭ 0.146 m), attached to the microscope. Fields were quantified under ϫ40 objective and ϫ0.5 reducing video camera adapter. The degree of emphysema was assessed by measuring in the alveolus the mean linear intercept (LM, m) using standard image analysis software (Leica Qwin v3, Leica Microsystems). Each data point represents the mean value of at least 18 randomly selected fields from six slides obtained from each lung.
In vivo detection of MMP activity by FMI. At 6 mo and 3 h after the last LGF injection, mice were injected via tail vein with MMPSense680, 2 nmol/150 l per mouse. MMPSense680 (PerkinElmer) is a protease-activatable fluorescent in vivo imaging agent that fluorochromes emit in the near-infrared (excitation: 680 nm; emission: 700 nm), allowing photons to penetrate for several centimeters in tissue. MMPSense680 is activated by key MMPs, including MMP-2, -3, -9, and -13, and is optically silent in its inactivated state and becomes highly fluorescent following the protease-mediated activation. The specificity of the fluorescent probe has already been proven by our group (33) . Twenty-one hours after MMPSense680 injection, mice were anesthetized during the imaging acquisition with a mixture of 2% isoflurane and 2 l/min oxygen using an Inhalation Anesthesia System (Harvard Apparatus), and hair from the thorax was removed by shaving and chemical depilation to acquire fluorescence molecular imaging. Mice were imaged using IVIS-Lumina Imaging System (Xenogen). Gray scale-reflected images and fluorescence-colorized images were superimposed and analyzed using the Living Image 3.1 software (Xenogen). The Living Image software uses a spectral unmixing technique for reducing the effects of native tissue autofluorescence and calculates the respective contribution of each on each pixel in the image (46) .
RNA isolation and real-time PCR. Total RNA was isolated using Trizol reagent from frozen lung samples and reverse-transcribed to cDNA. For real-time PCR, we used TaqMan universal master mix and Taqman gene expression assays for the following genes: mmp9 (Mm00442991_m1) and mmp2 (Mm00439498_m1) from Applied Biosystems. The 2-⌬⌬CT method was applied to get the gene expression data using the Rn18s gene as an internal control to normalize the expression of the target genes mentioned above.
Inflammatory cell infiltrate in bronchoalveolar lavage fluid. After the 6-mo study period, to perform bronchoalveolar lavage (BAL) fluid tests, animals were killed with an overdose of pentobarbital sodium (50 mg/kg body wt ip; Abbott Laboratories), and an endotracheal tube (22GA) was inserted to instill 1 ml of cold 0.9% NaCl and recover it by gentle manual aspiration. Cell viability was determined manually by using Trypan blue exclusion. For inflammatory cell measurement, the recovered BAL fluid was centrifuged at 600 g at 4°C for 5 min and decanted, and the BAL cell pellet was resuspended in 200 l of 0.9% NaCl; the total cell numbers were then determined by counting on a hemocytometer (cells ϫ 10 3 /ml).
Determination of leukocyte population profile by flow cytometry.
Immunostaining of BAL fluid and peripheral blood samples was performed using fluorochrome-conjugated monoclonal anti-mouse antibodies, CD3-FITC from BD Biosciences, Ly6B.2 (clone 7/4), Alexa Fluor647, and F4/80-Phycoerythrin from Serotec, directed at leukocyte surface markers to determine the T-lymphocytes, neutrophils, and alveolar macrophage/monocyte infiltration, respectively. The samples were stained, lysed, and washed before data acquisition on a dual-laser FACS Calibur flow cytometer running CELL Quest software (BD Biosciences) using an absolute counting protocol. List mode data were analyzed with Infinicyt software (Cytognos After the 6-mo study period, blood samples of mice were collected, and serums were prepared. Quantitative determination of protein levels of the cytokine TNF-␣ was made using cytokine ELISA Kit (Thermo Fisher Scientific) according to manufacturer's instruction. Briefly, 50 l of serum were loaded in triplicate in 96-well plates. The cytokine concentration was measured by optical densitometry at 450 nm in a SpectramaxPlus 384 microplate reader (Molecular Devices). The minimum detectable concentration was set to be 9 pg/ml (Thermo Fisher Scientific).
Statistical analysis. Data are presented as means Ϯ SE. P values of Ͻ0.05 were considered statistically significant. Variations in body weight over time were explored using t-tests and parametric tests. Mann-Whitney U-nonparametric test was performed for comparisons between groups of all the biological variables, followed by Monte Carlo's exact methods within each set of comparisons, using the Statistical Package for the Social Science (SPSS) software.
RESULTS
LGF treatment improves the lung function impairment of emphysematous mice. Pulmonary emphysema induced by chronic CSE produced a significant increase in C L (ml/cmH 2 O) of CSE group (0.18 ml/cmH 2 O Ϯ 0.003) compared with CTL group (0.14 ml/cmH 2 O Ϯ 0.0014).
LGF administration brought the functional variable closer to normal values, with statistically significant variations in C L of CSE ϩ LGF group (0.12 ml/cmH 2 O Ϯ 0.008) vs. CSE group (Fig. 1) .
LGF treatment reduces the alveolar airspace enlargement in a previously established chronic CSE-induced emphysema murine model. Chronic CSE induced pulmonary emphysema with alveolar airspace enlargement. Morphometric analysis of L M (m) showed a significant increase in the CSE group (28.47 m Ϯ 0.58) compared with CTL group (25.40 m Ϯ 0.7).
LGF treatment brought the L M morphometric variable closer to normal values, and significant reduction in the L M could be observed between CSE group and CSE ϩ LGF group (25.54 m Ϯ 0.43) (Fig. 2A) . Histological sections of lungs in CTL, after chronic CSE and after LGF treatment are shown in Fig. 2B .
LGF treatment decreases chronic CSE-mediated lung tissue remodeling enzyme activity. In vivo detection by FMI of MMP activity in lung parenchyma revealed a significantly increased chronic CSE-associated MMP activity of the CSE group (1.85 Ϯ 0.05/U) compared with the control CTL group (1 Ϯ 0.12/U). This increment was significantly decreased in the CSE ϩ LGF group (1.16 Ϯ 0.06/U) compared with the CSE group (Fig.  3A) . When we analyzed fluorescent images, the units were the ratio between emission and excitation light and were referred to as relative fluorescence intensity (arbitrary units). Images of each representative mouse of the study groups are displayed in Fig. 3B . To confirm which MMP is responsible for the observed effect of LGF, gene expression data of the MMPs most involved in the development of CSE-induced emphysema are shown (Fig. 4) . The MMP-2 mRNA level was significantly increased in the CSE group (1.43 Ϯ 0.03/U) compared with the CTL group (1 Ϯ 0.08/U). However, the increment of MMP-9 LGF treatment decreases the inflammatory cell infiltrate in BAL fluid after chronic CSE. In the BAL fluid of CSE mice, there were significantly increased total cell numbers (1,027 ϫ 10 3 Ϯ 73.04 cells/ml) compared with CTL mice (470 ϫ 10 3 Ϯ 57.95 cells/ml). Furthermore, there was a significant decrease in the total number of cells of BAL in CSE ϩ LGF mice (242 ϫ 10 3 Ϯ 25.04 cells/ml) compared with CSE mice (Fig. 5) .
LGF treatment changes the leukocyte profile after chronic CSE. Leukocyte population profile in the BAL fluid (Fig. 6 ) and peripheral blood (Fig. 7) samples of CSE mice were quantified by flow cytometry: T-lymphocytes, neutrophils, and monocytes/macrophages. The number of each leukocyte subject was then expressed as a percentage of the total number of positive events from the respective control value (per unit). With respect to the leukocyte population in the BAL fluid (Fig.  6A) , note the significant increase in alveolar macrophages in the CSE group (1.28 Ϯ 0.15/U) compared with the CTL group (1 Ϯ 0.08/U) and the increase in the number of neutrophils in the CSE ϩ LGF group (2.71 Ϯ 0.18/U) following treatment with the growth factor, compared with the CTL group (1 Ϯ 0.04/U). Our results in the peripheral blood (Fig. 7A) show a significant increase in the percentage of T-lymphocytes (1.39 Ϯ 0.11%) of the CSE group with respect to the airexposed group (CTL, 1 Ϯ 0.06%) and a significant decrease in the percentage of monocytes (0.89 Ϯ 0.03%) in the peripheral blood of CSE group with respect to the air-exposed group (CTL, 1 Ϯ 0.05%). However, significant changes in the percentage of neutrophils were not appreciated. This significant increase of T-lymphocytes and decrease of monocytes in the peripheral blood were decreased (0.59 Ϯ 0.03%) and increased LGF treatment reduces the serum TNF-␣ level after chronic CSE. Levels of the cytokine TNF-␣ were significantly greater in the peripheral blood of the CSE mice (362 Ϯ 25.93 pg/ml) than CTL animals (267 Ϯ 9.73 pg/ml).
LGF treatment brought TNF-␣ blood levels closer to normal values (315 Ϯ 20.25 pg/ml) but not significantly (Fig. 8) .
DISCUSSION
In the present study, it is demonstrated for the first time the LGF therapeutic effect on chronic CSE in a AKR/J mouse model of COPD, improving indicators and parameters of systemic inflammation, physiology, and morphology of the lungs. In this regard, the main findings in this study are that mice treated with LGF after chronic CSE (6 mo) exhibit the following modifications compared with control animals: 1) improved lung function impairment, 2) reduced alveolar airspace enlargement, 3) decreased chronic CSEmediated lung tissue remodeling enzyme activity, 4) reduced inflammatory cell infiltrate in BAL fluid, and 5) changed circulating leukocyte profile in peripheral blood, with decreasing T-lymphocyte population, tending to reduce neutrophil infiltration, and increasing monocyte population. . Data are expressed as means Ϯ SE (n ϭ 10/group, *P Ͻ 0.05). B: representative images (ϫ10 magnification) corresponding to lung specimens. Note that the size of the alveoli is larger in the CSE than in the CTL and CTL ϩ LGF mice, and this alveolar structure is practically reversed in the CSE ϩ LGF group.
Considering these data, we suggest that LGF could be a relevant anti-inflammatory and lung structure and function regenerative molecule, particularly in situations of lung injury induced by CSE.
COPD is associated with systemic effects, including reduced body weight gain and altered circulating leukocytes and plasma TNF-␣ levels. CSE mice gained body weight, although to a lesser extent compared with CTL animals, up to the third month of exposure. Although not specifically quantified, food intake between CSE and CTL rodents was similar, even after 3 mo of study (animals in both groups were always fed ad libitum, receiving an identical amount of food/day per animal in the cages). The present findings are in line with previous investigations, where animals chronically exposed to cigarette smoke also underwent a significant reduction in body weight gain (2, 20) . The long-term intraperitoneal administration of LGF doses (1.7 g/animal) in AKR/J mice was well tolerated, with no toxicity in terms of body weight gain. In summary, AKR/J mice chronic exposure to cigarette smoke induces lung emphysema concomitantly with greater modifications on body weight gain, total cell count in BAL fluid, MMP activity in living mice, physiological and morphological lung parameters, serum TNF-␣ levels, and change in the profile of circulating leukocytes. Treatment with LGF seems to reverse all these parameters studied, except the loss of body weight and TNF-␣ level, although the latter if it tends to decrease. LGF treatment decreases the MMP-9 expression in the CSE ϩ LGF group (shaded bar) compared with CTL group (open bar). Results are expressed as means Ϯ SE (n ϭ 6/group, *P Ͻ 0.05) in % relative to nonexposed and nontreated mice that were arbitrarily assigned a value of 1%.
In the current investigation, AKR/J mice exposed to cigarette smoke for 6 mo exhibited a significant increase in the C L (28%) and in the L M , alveolar airspace enlargement (12%), suggesting the development of emphysema in these animals compared with nonexposed control animals. These findings are in agreement with other previous studies (20) . Both of these parameters were reduced with the LGF treatment by 50% and 11%, respectively.
The presence of inflammation after chronic CSE in AKR/J mice was confirmed by increased inflammatory cell infiltrate in BAL fluid and by increased lung tissue remodeling enzyme activity measured in living mice. These findings are in agreement with other previous studies (47) , but the novelty is the technique used to measure lung protease activity in vivo. Enzyme-based activatable probes for fluorescence-mediated imaging has proven valuable for the detection of tumor-associated lysosomal protease activity in an animal model (5, 45) , and we have recently demonstrated that MMP-activatable probe can be used to detect MMP activity in the lung tissue after acute CSE (33) . With the help of an activatable sensor that reports activity, we have demonstrated in the present study that MMP activity, visualized by fluorescence molecular imaging in the lung of living mice, is significantly decreased in LGF-treated mice after smoking-induced emphysema. The data presented herein serve to further evince molecular imaging as a technology highly appropriate for chronic lung inflammatory research.
LGF treatment appears to reverse gene expression of MMP-9 in the lung tissue but not MMP-2. MMP-9 is produced mainly by inflammatory cells and could be rather linked to inflammatory process-induced tissue remodeling (10, 19, 40) . However, MMP-2 is synthesized by structural cells and is more associated with the impaired tissue remodeling, leading to pathological collagen deposition and interstitial fibrosis. We consider that decreasing MMP-9 participates in early changes, as a consequence of the anti-inflammatory effect of LGF and MMP2 could possibly decrease later, while the process continues. We notice that the reversibility changes were studied only 15 days after LGF administration. Systemic inflammation in COPD is also characterized by cytokines systemically implicated in inflammatory cell recruitment and airway remodeling. Our data suggest that animals with chronic airflow limitation had significantly raised levels of various systemic inflammatory markers like circulating leukocytes (specifically T-cells and neutrophils) and serum TNF-␣ level, indicating that persistent systemic inflammation is present in AKR/J. LGF treatment decreases T-lymphocyte population in peripheral blood, what seems to be in agreement with a recently published article that shows that T-cell depletion protects against alveolar destruction attributable to chronic CSE in mice (37) . It is possible in some cases that the inflammatory process may "spill" over into the systemic circulation, promoting a generalized inflammatory reaction. Our findings are consistent with systemic inflammation present in some patients with COPD (1) associated with an increased influx of T-cells into the airway (6, 28, 31, 37) . This finding may explain, at least in part, the high prevalence of systemic complications, such as cachexia, osteoporosis, and cardiovascular diseases among patients with COPD. Future studies are needed to determine whether attenuation of the systemic inflammatory process can modify the risk of these complications in COPD.
In view of the results obtained in this study, what seems clear is that LGF treatment promotes tissue regeneration, probably by promoting cell proliferation (7, 18, 39, 42) of the lung parenchyma. Maybe the LGF stimulates cellular antioxidant response (8, 9) or decreases cellular apoptotic processes (13) . However, further studies are necessary to get to know the mechanism by which it acts. In summary, there is now a large body of evidence to indicate that LGF treatment reverses emphysema previously established in a chronic CSE mouse model, normalizing the physiological and morphological data and levels of various systemic inflammatory markers, which may have important pathophysiological and therapeutic implications for subjects with stable COPD. 
